Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05661851Phase 2Completed
Phase 2, randomised, single-blind trial in dry eye syndrome (DED) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in Overall Quality of Ocular Comfort at 30 days. Started Feb 2023; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05661851.